{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T03:15:25Z","timestamp":1775186125220,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.jbspin.2020.04.010","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T04:14:37Z","timestamp":1588824877000},"page":"475-479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Early discontinuation of tofacitinib in patients with rheumatoid arthritis co-treated with rifampin for latent tuberculosis"],"prefix":"10.1016","volume":"87","author":[{"given":"So Hye","family":"Nam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Seon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seokchan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Sun","family":"Shim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Keun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Gil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2020.04.010_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2020.04.010_bib0120","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.04.010_bib0125","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.04.010_bib0130","first-page":"28","article-title":"Controlled chemoprophylaxis trials in tuberculosis. A general review","volume":"26","author":"Ferebee","year":"1970","journal-title":"Bibl Tuberc"},{"key":"10.1016\/j.jbspin.2020.04.010_bib0135","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/infdis\/jis269","article-title":"Risk of tuberculosis reactivation with tofacitinib (CP-690550)","volume":"205","author":"Maiga","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jbspin.2020.04.010_bib0140","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/2150131912437936","article-title":"Poor compliance makes treatment of latent tuberculosis infection unsatisfactory","volume":"3","author":"Larppanichpoonphol","year":"2012","journal-title":"J Prim Care Community Health"},{"key":"10.1016\/j.jbspin.2020.04.010_bib0145","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12879-017-2245-8","article-title":"Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine","volume":"17","author":"McClintock","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jbspin.2020.04.010_bib0150","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2005.046797","article-title":"BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-\u03b1 treatment","volume":"60","author":"British Thoracic Society Standards of Care Committee","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.jbspin.2020.04.010_bib0155","unstructured":"Pfizer Laboratories Div Pfizer Inc. XELJANZ- tofacitinib tablet, film coated, XELJANZ XR- tofacitinib tablet, film coated, extended release, https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=cf74ba2f-afc5-4baa-8594-979c889a5831;.[accessed 19.12.21]."},{"key":"10.1016\/j.jbspin.2020.04.010_bib0160","article-title":"The effect of rifampin on the pharmacokinetics of tofacitinib (CP-690, 550) in healthy volunteers","volume":"91","author":"Lamba","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jbspin.2020.04.010_bib0165","series-title":"7th Korea National Health and Nutrition Examination Survey 1st year (2016) tuberculin survey support and quality control","author":"The Korea National Tuberculosis Association","year":"2017"},{"key":"10.1016\/j.jbspin.2020.04.010_bib0170","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1590\/S0482-50042010000500001","article-title":"2010 ACR-EULAR classification criteria for rheumatoid arthritis","volume":"50","author":"Villeneuve","year":"2010","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.jbspin.2020.04.010_bib0175","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3109\/00365548.2014.938691","article-title":"Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay","volume":"46","author":"Kim","year":"2014","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jbspin.2020.04.010_bib0180","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cid\/ciw778","article-title":"Official American Thoracic Society\/Infectious Diseases Society of America\/Centers for Disease Control and Prevention Clinical Practice Guidelines: diagnosis of tuberculosis in adults and children","volume":"64","author":"Lewinsohn","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jbspin.2020.04.010_bib0185","series-title":"Korean Guidelines for Tuberculosis","author":"Joint Committee for the Revision of Korean Guidelines for Tuberculosis","year":"2017"},{"key":"10.1016\/j.jbspin.2020.04.010_bib0190","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2020.04.010_bib0195","series-title":"Annual Report on the Notified Tuberculosis in Korea 2017","author":"Korea Centers for Diseases Control and Prevention","year":"2018"},{"key":"10.1016\/j.jbspin.2020.04.010_bib0200","doi-asserted-by":"crossref","first-page":"e2018036","DOI":"10.4178\/epih.e2018036","article-title":"Tuberculosis control in the Republic of Korea","volume":"40","author":"Cho","year":"2018","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.jbspin.2020.04.010_bib0205","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/acr.23585","article-title":"Tofacitinib in rheumatoid arthritis: lack of early change in disease activity and the probability of achieving low disease activity at month 6","volume":"71","author":"van Vollenhoven","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2020.04.010_bib0210","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/bmj.286.6369.923","article-title":"Rifampicin reduces effectiveness and bioavailability of prednisolone","volume":"286","author":"McAllister","year":"1983","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.jbspin.2020.04.010_bib0215","doi-asserted-by":"crossref","first-page":"s440","DOI":"10.1093\/clinids\/5.Supplement_3.S440","article-title":"Adverse effects of rifampin","volume":"5","author":"Grosset","year":"1983","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.jbspin.2020.04.010_bib0220","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0041-3879(75)90049-5","article-title":"The influence of age and sex on the incidence of the \u2018flu\u2019 syndrome and rifampicin-dependent antibodies in patients on intermittent rifampicin for, tuberculosis","volume":"56","author":"Hong Kong Tuberculosis Treatment Services","year":"1975","journal-title":"Tubercle"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X20300750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X20300750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:27:48Z","timestamp":1761150468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X20300750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1297319X20300750"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2020.04.010","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early discontinuation of tofacitinib in patients with rheumatoid arthritis co-treated with rifampin for latent tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2020.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}